Pharmaceuticals: Beating the Hell Out of the Average
Bichler, Shimshon and Nitzan, Jonathan.
(2021).
Research Note. June. pp. 1-5.
(Article - Working Paper; English).
Preview |
Cover Image
20210600_bn_pharmaceuticals_beating_the_hell_out_of_the_average_rn_front.jpg Download (25kB) | Preview |
Preview |
PDF (Full Text)
20210600_bn_pharmaceuticals_beating_the_hell_out_of_the_average_rn.pdf Download (491kB) | Preview |
HTML (Full Text)
20210600_bn_pharmaceuticals_beating_the_hell_out_of_the_average_rn_web.htm Download (22kB) |
|
Other (Excel data for the figure)
20210600_bn_pharmaceuticals_beating_the_hell_out_of_the_average_rn_data.xlsx Download (55kB) |
|
Preview |
Other (Figure 1)
fig01.JPG Download (231kB) | Preview |
Preview |
Other (Figure 2)
fig02.JPG Download (216kB) | Preview |
Alternative Locations
https://www.econstor.eu/handle/10419/234557, https://www.academia.edu/49173148/Pharmaceuticals_Beating_the_Hell_Out_of_the_Average
Abstract or Brief Description
A lot has been written on the imminent decline of pharmaceuticals: their falling production, reduced R&D, declining innovation, the opioid crisis, patent cliffs, biting competition from generic drugs, growing opposition to IPR. The list goes on. Judging by the yardsticks that matter the most, though – namely, the companies’ relative profit and relative capitalization – pharmaceuticals are doing just fine. In fact, based on these yardsticks, they remain the most powerful corporate sector of all.
Language
EnglishPublication Type
Article - Working PaperKeywords
capitalization finance pharmaceutical power profitSubject
BN International & GlobalBN Money & Finance
BN Power
BN Science & Technology
BN Value & Price
BN Business Enterprise
BN Capital & Accumulation
BN Distribution
Depositing User
Jonathan NitzanDate Deposited
08 Jun 2021 17:02Last Modified
09 Jun 2021 16:45URL:
https://bnarchives.net/id/eprint/693Actions (login required)
View Item |